LYR-210 AN INNOVATIVE THERAPEUTIC SOLUTION FOR CRS

Lyra’s lead product candidate, LYR-210, has completed Phase 2 clinical development to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra’s XTreo™ platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients.

LYR-210’s unique properties address the challenges of CRS

Locally targeted
LYR-210 is delivered directly to the inflamed mucosal tissues, where its design optimizes surface area for local release and absorption of anti-inflammatory medication.
Anti-inflammatory
LYR-210 delivers mometasone furoate, a known potent anti-inflammatory agent. In its Phase 2 study, LYR-210 demonstrated rapid and durable improvements in symptom severity for most polyp and non-polyp patients.
Long acting
LYR-210 gradually releases mometasone furoate for over six months. Its flexible design conforms to the patient’s nasal anatomy and is designed to be unobtrusive to patients.
Accessible
LYR-210 is administered in an ENT office setting in a short procedure using a topical anesthetic and is designed to eliminate the need for other costly and more invasive CRS interventions.

HERE’S HOW LYR-210 WORKS

BEFORE LYR-210 TREATMENT

CRS patients experience at least two of the four cardinal symptoms (4CS) for more than 12 weeks, including nasal blockage, facial pain and pressure, nasal discharge, and decreased sense of smell. Persistent and severe symptoms cause sleep disturbances, daytime fatigue, depression, and anxiety, which significantly negatively impact quality of life for the CRS sufferer.

AFTER LYR-210 TREATMENT

Inflammation subsides as anti-inflammatory medicine is continually released directly to tissues. The mesh scaffold conforms to stay in place as inflammation recedes, offering up to six months of symptom improvement from a single treatment.

DESIGNED FOR IMPACT AT SITE OF CRS

LYR-210 enables long-acting therapy directly to the site of CRS inflammation, offering an alternative to address limitations of current CRS treatments

  • Topical nasal steroid sprays are not effective at reaching the site of inflammation deep within the nasal passages or maintaining a therapeutic concentration over time
  • Surgical interventions do not directly address underlying inflammation, lead to painful recovery, and often require additional surgery

LYR-210 ON CLINICAL PATH FOR CRS

Lyra has announced positive results for its LANTERN Phase 2 study of LYR-210 for the treatment of CRS, including:

  • 7500 mcg dose achieved statistically significant improvement in a composite score of the four cardinal symptoms of CRS compared to control
  • 7500 mcg achieved statistically significant improvement in SNOT-22 compared to control
  • LYR-210 is the first nasal implant in clinical testing to achieve a benefit of up to six months after a single administration, and the first nasal implant to achieve a benefit in both polyp and non-polyp patients

See video presentation of LANTERN study results here.

  • CRS is a chronic, lifelong condition, and there continues to be a need for innovation for the millions of people suffering from this inflammatory disease.  As such, the LANTERN results are very encouraging, particularly as there are no FDA approved therapeutics for CRS patients without nasal polyps, despite that patient population representing approximately 70-90% of all CRS patients.

    Robert Kern, MD
    Chief Medical Officer, Lyra
    George A. Sisson Professor and Chair, Department of Otolaryngology – Head and Neck Surgery, Northwestern University Feinberg School of Medicine

  • The LANTERN study results are very exciting to those of us in the ENT community who are eager to embrace new treatment options for CRS, including alternatives to surgery.  Based on my experience in Lyra’s Phase 1 and Phase 2 studies for LYR-210, I believe a drug-releasing nasal implant that may offer up to six months treatment would represent an important innovation for CRS patients.

    Joanne Rimmer, MD
    LANTERN study investigator
    ENT surgeon and rhinologist, Monash Health
    Associate Professor, Monash University

  • I believe this innovative long-acting investigational treatment has the potential to make a meaningful positive impact on patients’ quality of life and offer an appealing alternative to invasive medical procedures.

    Robert Kern, MD
    Chief Medical Officer, Lyra
    George A. Sisson Professor and Chair, Department of Otolaryngology – Head and Neck Surgery, Northwestern University Feinberg School of Medicine

  • The in-office procedure of placing LYR-210 into a patient’s nose is straightforward, suggesting that LYR-210 may have the potential to improve the quality of life for patients who have failed medical management while offering an alternative to invasive medical procedures.

    Joanne Rimmer, MD
    LANTERN study investigator
    ENT surgeon and rhinologist, Monash Health
    Associate Professor, Monash University

Back to Top